

Commercial & Healthcare Exchange PA Criteria

Effective: February 11, 2020

Prior Authorization: Minocycline topical foam

Products Affected: Amzeeq (minocycline) 4% topical foam, Zilxi (minocycline) 1.5% topical foam

Medication Description: Minocycline is one of several broad-spectrum antibiotics known as tetracyclines with anti-inflammatory properties. It is primarily bacteriostatic and acts by inhibiting protein synthesis. It has a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms as other tetracyclines. The mechanism of action of Amzeeq for the treatment of acne is unknown. The mechanism of action of Zilxi for the treatment of inflammatory lesions of rosacea is unknown.

Covered Uses:

Amzeeq: Topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older.

Zilxi: Topical treatment of inflammatory lesions of rosacea in adults.

Exclusion Criteria:

1. Used for the treatment of infections (not acne related) – Amzeeq only
2. Known hypersensitivity to any of the tetracyclines

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions:

Amzeeq: 9 years of age or older

Zilxi: 18 years of age or older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

Amzeeq (minocycline) 4% topical foam

- A. Patient has a diagnosis of non-nodular moderate to severe acne vulgaris; **AND**
- B. Patient has tried at least TWO formulary alternatives (e.g., Benzoyl peroxide/clindamycin, Benzoyl peroxide, Clindamycin, Clindamycin Phosphate/Benzoyl peroxide, Sodium sulfacetamide, Erythromycin gel, Erythromycin-Benzoyl).

Zilxi (minocycline) 1.5% topical foam

- A. Patient has a diagnosis of rosacea; **AND**
- B. Patient has a documented intolerance, contraindication, or treatment failure to one of the following: metronidazole cream, metronidazole lotion, or metronidazole gel.

References:

1. Amzeeq (minocycline) [prescribing information]. Bridgewater, NJ: Foamix Pharmaceuticals Inc; October 2019.
2. Amzeeq. Lexi-Drugs [database online]. Hudson, OH: Lexicomp Inc; 2014. <http://online.lexi.com>. Accessed January 26th, 2020
3. Zilxi (minocycline) [prescribing information]. Bridgewater, NJ: Foamix Pharmaceuticals Inc; May 2020.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	2/11/20
2	Update	Renamed policy from Amzeeq to minocycline topical foam Medication description updated Zilxi added to products affected, covered uses, age restrictions, other criteria	All	7/16/20